Drugs
FDA’s OCP Maps Out AI, Modeling and Evidence Priorities
FDA’s Office of Clinical Pharmacology (OCP) says regulatory science will have to evolve alongside increasingly complex therapies, with greater use of quantitative modeling, artificial intelligence and translational evidence expected to play a role in future drug development and regulatory decisions. In a just-posted Office of Clinical Pharmacology annual